GlassScriptPhysician profile
Robert V Sica
NPI 1386623593
$5,097.91
in general payments reported to CMS, 2019-2025
33 companies · $800 in 2025
The $800 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $827 · 2020: $318 · 2021: $296 · 2022: $834 · 2023: $1,047 · 2024: $976 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,823.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $613.72 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $531.01 | 2019-2025 | Jardiance, Emgality, Synjardy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $468.65 | 2019-2024 | Synjardy, Jardiance, Ofev |
| Novartis Pharmaceuticals Corporation | $403.84 | 2019-2025 | |
| Glaxosmithkline, LLC. | $377.08 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $310.55 | 2019-2025 | Vraylar, Ubrelvy, Linzess |
| Merck Sharp & Dohme LLC | $284.47 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Pfizer INC. | $208.94 | 2019-2024 | |
| Daiichi Sankyo INC. | $197.61 | 2019-2024 | Injectafer |
| Kowa Pharmaceuticals America, INC. | $197.10 | 2019-2025 | Livalo, Zoryve |
| Otsuka America Pharmaceutical, INC. | $170.72 | 2023-2025 | Rexulti |
| Cvrx, INC. | $169.00 | 2023 | Barostim Neo System |
| Novo Nordisk INC | $167.26 | 2019-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $151.43 | 2022-2025 | Freestyle Libre 3 |
| Enterra Medical, INC. | $116.91 | 2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $108.84 | 2019-2025 | Repatha, Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $101.06 | 2019-2023 | Eliquis |
| Xeris Pharmaceuticals, INC. | $83.18 | 2025 | Recorlev |
| Astellas Pharma US INC | $76.46 | 2023 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $47.01 | 2019 | |
| Phathom Pharmaceuticals, INC. | $42.63 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $39.58 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $39.53 | 2025 | |
| Exact Sciences Corporation | $35.02 | 2024 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $29.15 | 2025 | Nexletol |
| Ultragenyx Pharmaceutical INC. | $21.66 | 2022 | |
| Shield Therapeutics INC | $19.80 | 2024 | |
| Intuity Medical INC | $19.40 | 2022 | |
| Arbor Pharmaceuticals, INC. | $19.06 | 2019 | |
| Corcept Therapeutics | $18.13 | 2025 | Korlym |
| Allergan, INC. | $16.50 | 2020 | |
| Vistapharm, INC. | $12.61 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Sica listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.